darolutamide,apalutamide,crizanlizumab,nivolumab
bayer,novartis,janssen,Ono Pharma,BMS
['apa ', 'crpc', 'spartan', 'aramis']
analysis of 200 nmcrpc pts undergoing psma-pet (spartan/prosper/aramis-like cohort): median os: 6 yrs (same as apa arm in spartan) pet-detected polymets (5+ lesions) os (hr=1.8; p=0.024) &amp; new metastases-free survival (median 38 vs 60 months, p=0.02) #asco23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @MCG_Urology and @AUB_Lebanon 🇱🇧